HomeCompareGZPHF vs EQR

GZPHF vs EQR: Dividend Comparison 2026

GZPHF yields 4.78% · EQR yields 4.73%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GZPHF wins by $61.8K in total portfolio value
10 years
GZPHF
GZPHF
● Live price
4.78%
Share price
$2.34
Annual div
$0.11
5Y div CAGR
32.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.2K
Annual income
$29,184.44
Full GZPHF calculator →
EQR
EQR
● Live price
4.73%
Share price
$58.58
Annual div
$2.77
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.5K
Annual income
$3,819.61
Full EQR calculator →

Portfolio growth — GZPHF vs EQR

📍 GZPHF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGZPHFEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GZPHF + EQR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GZPHF pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GZPHF
Annual income on $10K today (after 15% tax)
$406.66/yr
After 10yr DRIP, annual income (after tax)
$24,806.77/yr
EQR
Annual income on $10K today (after 15% tax)
$401.93/yr
After 10yr DRIP, annual income (after tax)
$3,246.67/yr
At 15% tax rate, GZPHF beats the other by $21,560.11/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GZPHF + EQR for your $10,000?

GZPHF: 50%EQR: 50%
100% EQR50/50100% GZPHF
Portfolio after 10yr
$71.3K
Annual income
$16,502.02/yr
Blended yield
23.13%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

GZPHF
No analyst data
Altman Z
2.4
Piotroski
4/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+20.1% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GZPHF buys
0
EQR buys
0
No recent congressional trades found for GZPHF or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGZPHFEQR
Forward yield4.78%4.73%
Annual dividend / share$0.11$2.77
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR32.3%15.8%
Portfolio after 10y$102.2K$40.5K
Annual income after 10y$29,184.44$3,819.61
Total dividends collected$73.4K$16.9K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: GZPHF vs EQR ($10,000, DRIP)

YearGZPHF PortfolioGZPHF Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$11,333$632.95$11,248$547.57+$85.00GZPHF
2$13,013$886.93$12,701$666.53+$312.00GZPHF
3$15,183$1,259.23$14,405$814.59+$778.00GZPHF
4$18,063$1,816.62$16,413$999.84+$1.6KGZPHF
5$21,999$2,672.13$18,795$1,232.92+$3.2KGZPHF
6$27,563$4,023.99$21,639$1,527.95+$5.9KGZPHF
7$35,726$6,233.83$25,057$1,903.80+$10.7KGZPHF
8$48,218$9,990.59$29,197$2,385.87+$19.0KGZPHF
9$68,265$16,671.91$34,250$3,008.70+$34.0KGZPHF
10$102,228$29,184.44$40,467$3,819.61+$61.8KGZPHF

GZPHF vs EQR: Complete Analysis 2026

GZPHFStock

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited, together with its subsidiaries, engages in the research, development, manufacture, and sale of Chinese patent and Western medicines, chemical raw materials, natural and biological medicines, and intermediates of chemical raw materials in the People's Republic of China and internationally. The company operates through four segments: Great Southern TCM, Great Commerce, Great Health, and Others. It is also involved in the wholesale, retail, import, and export of Western and Chinese medicines, and medical apparatus and instruments; and research and development, production, and sale of beverages, food, healthcare products, pre-packaging food, dairy products, tablets, capsules, lozenges, injections, tortoise herb jelly, etc. In addition, the company invests in health industry, such as medical care, health management, health preservation, elderly care, etc.; and provides commercial and advertising services. As of December 31, 2021, it had 154 retail chain pharmacy outlets, which included 22 Cai Zhi Lin pharmacy outlets, 36 Jian Min pharmacy outlets, 51 GPC Prescription Pharmacy outlets, and 23 Hainan Guangyao Chenfei Pharmaceutical Chain Co., Ltd outlets, as well as 22 retail stores. The company was formerly known as Guangzhou Pharmaceutical Company Limited and changed its name to Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited in August 2013. Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited was incorporated in 1997 and is based in Guangzhou, China.

Full GZPHF Calculator →

EQRREIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this GZPHF vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GZPHF vs SCHDGZPHF vs JEPIGZPHF vs OGZPHF vs KOGZPHF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.